Effect of riluzole on dyskinesia and duration of the ON state in Parkinson disease patients - A double-blind placebo-controlled pilot study

Effect of riluzole on dyskinesia and duration of the ON state in Parkinson disease patients - A double-blind placebo-controlled pilot study

Author Braz, C. A. Google Scholar
Borges, V Google Scholar
Ferraz, H. B. Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract The objective of this study was to evaluate the effect of riluzole on dyskinesia and the duration of the ON state in patients with Parkinson disease (PD). the authors studied 16 PD patients with levodopa-induced dyskinesia. All patients initially received an apomorphine dose intended to induce the motor function benefit (ON state) generally accompanied by dyskinesia. They evaluated the patients during the OFF and ON states using the UPDRS-III, UPDRS-IV, and Larsen scales, and measured the duration of the ON state. Patients were randomly assigned to receive either riluzole (50 mg bid) or placebo for 7 consecutive days (8 patients in each group). the authors did not interrupt previously prescribed medication. Following the 7-day period, they carried out similar evaluation procedures before and after another apomorphine challenge. Mean UPDRS-IV scores were 6.1 points and 6.0 points before and after riluzole therapy respectively. for the placebo group, the scores were 6.9 points and 6.6 points for the initial and final evaluations respectively. Larsen scale had mean scores of 9.2 points and 9.9 points for the pre- and postriluzole periods, and 10.2 points and 9.6 points for pre- and post-placebo evaluations respectively. the ON state was 33.5% lengthier after 7 days of riluzole and 28.0% lengthier after placebo. They could not find any statistical differences between the 2 groups. Short-term riluzole administration in PD patients was not able to reduce apomorphine-induced dyskinesia but could extend the ON state duration, although this did not reach statistical significance.
Keywords Parkinson disease
treatment complications
levodopa
apomorphine
dyskinesia
riluzole
antiglutamate drugs
Language English
Date 2004-01-01
Published in Clinical Neuropharmacology. Philadelphia: Lippincott Williams & Wilkins, v. 27, n. 1, p. 25-29, 2004.
ISSN 0362-5664 (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 25-29
Origin http://dx.doi.org/10.1097/00002826-200401000-00008
Access rights Closed access
Type Review
Web of Science ID WOS:000220024300008
URI http://repositorio.unifesp.br/handle/11600/27563

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account